Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Dec 22, 2017 (9 years ago)

Simvastatin Tablets

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Presence of foreign substance: metallic razor blade was found in one bottle.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Simvastatin Tablets, USP, 40 mg, 1000-count bottle, Rx only, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway, NJ 08854, Manufactured by: Hetero (trademark), Hetero Labs Limited, Jeedimetla, Hyderabad - 500 055, India, NDC 31722-513-10

Affected NDC 31722-0513-10

Compare with the code on your package — it is the most precise check available.

Drug: Simvastatin Category: Cholesterol Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Simvastatin
NDC 31722-0513
40 mg/1 Tablet, Film Coated
Oral
Camber Pharmaceuticals, Inc. Rx
Recalling firm
Hetero Labs, Ltd. - Unit III
NDC code
31722-513-10
Origin
N/A, India
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0223-2018 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Simvastatin recalls

See all
Class III · Low risk

Ezetimibe and Simvastatin Tablets

Failed Impurities/Degradation Specifications: Out of Specification (OOS) for related substances test for Anhydro Simvastatin at the 06-month time point during long-term stability study.

Ongoing Impurity / degradation Glenmark Pharmaceuticals Inc., USA NDC 68462-323-90 D-0462-2025
Class II · Moderate risk

Simvastatin USP

CGMP deviations.

Terminated cGMP deviation PD-Rx Pharmaceuticals, Inc. NDC 43063-0727-30 D-0558-2023
Class II · Moderate risk

Simvastatin Tablets

cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.

Ongoing cGMP deviation Preferred Pharmaceuticals, Inc. NDC 68788-9868-9 D-0525-2023

Other recalls by Hetero Labs, Ltd. - Unit III

All 2017 recalls
Class III · Low risk

Fenofibrate Tablets

Presence of Foreign Tablet/Capsule: A foreign identified as Valacyclovir tablet 500 mg was co-mingled in a bottle containing Fenofibrate Tablets, USP 145 mg.

Terminated Particulate / foreign matter Hetero Labs, Ltd. - Unit III NDC 31722-596-90 D-1211-2018
Class II · Moderate risk

Indomethacin Capsules

Failed Tablet/Capsule Specifications: customer complaints of deformed, clumped, misshaped, melted or stuck together capsules.

Terminated Failed specification Hetero Labs, Ltd. - Unit III NDC 31722-543-01 D-1019-2018
Class II · Moderate risk

Aripiprazole Tablets

CGMP Deviations: lot made with active pharmaceutical ingredient that did not meet all its intended specifications.

Terminated cGMP deviation Hetero Labs, Ltd. - Unit III NDC 31722-827-30 D-0594-2018